Seeking Alpha
09 Mar 2026, 14:20 UTC · 27w ago
Verdict
Headline takes no side. We score TMDX +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
TransMedics delivered a robust Q4 with 32% year-over-year revenue growth and earnings that exceeded estimates.
More positive than 98% of claims this week
Operating margins expanded by over 610 basis points in the most recent quarter.
So whatSignificant margin expansion indicates operational leverage and a shift toward sustainable profitability.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 91% of claims this week
Management has provided guidance for 20-25% revenue growth in 2026.
So whatForward guidance provides a baseline for valuation models and suggests a steady long-term growth runway.
More positive than 84% of claims this week
The company sees significant upside potential from its Heart, Lung, and Kidney programs alongside its dominant Liver segment.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported strong Q4 results, exceeded estimates, and provided positive future growth guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
23h ago
−33.3%
Price is moving against the score
$86.43 vs $129.61 close before publication (Mar 6) · not market-adjusted
TMDX chart →
